An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
Anti-obesity drug Mounjaro is set rack up sales of nearly £22bn a year by 2030. But Trump's 'America First' policies mean Britons could soon be paying more for the 'King Kong' of weight-loss jabs ...
Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...
Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...